The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment ... or occupational dust. Also ...

2 Top Growth Stocks to Buy on the Dip was originally published by The Motley Fool ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

Researchers are exploring how small airway abnormalities in younger smokers could help identify who is at risk of developing COPD and establish how the chronic lung disease progresses.

SIOUX CITY (KTIV) - The World Health Organization says chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, causing 3.23 million deaths in 2019. COPD is ...

After years of limited advancements in chronic obstructive pulmonary disease (COPD ... or occupational dust. Also Read: Regeneron’s Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees ...

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...

The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...